Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Extension and Safety Monitoring Study of Patients With Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201

Trial Profile

An Open-Label Extension and Safety Monitoring Study of Patients With Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2018

At a glance

  • Drugs AG 10 (Primary)
  • Indications Amyloidosis; Cardiomyopathies
  • Focus Adverse reactions
  • Sponsors Eidos Therapeutics
  • Most Recent Events

    • 09 Aug 2018 Planned End Date changed from 1 Dec 2018 to 1 Jul 2023.
    • 09 Aug 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2023.
    • 11 Jul 2018 Planned number of patients changed from 45 to 55.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top